Alzheimer's disease causes a progressive dementia that currently affects over 35 million individuals worldwide and is expected to affect 115 million by 2050 (ref. 1) . There are no cures or disease-modifying therapies, and this may be due to our inability to detect the disease before it has progressed to produce evident memory loss and functional decline. Biomarkers of preclinical disease will be critical to the development of disease-modifying or even preventative therapies 2 . Unfortunately, current biomarkers for early disease, including cerebrospinal fluid tau and amyloid-b levels 3 , structural and functional magnetic resonance imaging 4 and the recent use of brain amyloid imaging 5 or inflammaging 6 , are limited because they are either invasive, time-consuming or expensive. Blood-based biomarkers may be a more attractive option, but none can currently detect preclinical Alzheimer's disease with the required sensitivity and specificity 7 . Herein, we describe our lipidomic approach to detecting preclinical Alzheimer's disease in a group of cognitively normal older adults. We discovered and validated a set of ten lipids from peripheral blood that predicted phenoconversion to either amnestic mild cognitive impairment or Alzheimer's disease within a 2-3 year timeframe with over 90% accuracy. This biomarker panel, reflecting cell membrane integrity, may be sensitive to early neurodegeneration of preclinical Alzheimer's disease.
We enrolled 525 community-dwelling participants, aged 70 and older and otherwise healthy, into this 5-year observational study. Over the course of the study, 74 participants met criteria for amnestic mild cognitive impairment (aMCI) or mild Alzheimer's disease (AD) (Online Methods); 46 were incidental cases at entry, and 28 phenoconverted (Converters) from nonimpaired memory status at entry (Converter pre ). The average time for phenoconversion to either aMCI or AD was 2.1 years (range 1-5 years). We defined three main participant groups in this paper: aMCI/AD, Converter and Normal Control (NC). The participants with aMCI and mild AD were combined into a single group (aMCI/AD) because this group was defined by a primary memory impairment, and aMCI is generally thought to reflect the earliest clinically detectable stage of AD. The aMCI/AD group included the Converters after phenoconversion. The Converters were included at two time points, prior to phenoconversion (Converter pre ), when memory was not impaired, and after phenoconversion ( post ), when memory was impaired and they met criteria for either aMCI or AD. The NC group was selected to match the whole aMCI/AD group on the basis of age, education and sex. In the third year of the study, we selected 53 participants with either aMCI or AD for metabolomic and lipidomic biomarker discovery. Included in this aMCI/AD group were 18 Converters. We also selected 53 matched cognitively normal control (NC) participants. For the Converters, blood from both time 0 (at entry to the study) and after phenoconversion was used; for the other subjects, blood from the last available visit was used. We used an internal cross-validation procedure to evaluate the accuracy of the discovered lipidomics profile in classifying 41 additional subjects, consisting of the remaining subset of 21 participants with aMCI/AD, including 10 Converters, and 20 matched NC participants (Supplementary Table 1 and Supplementary Fig. 1) .
The aMCI/AD, Converter and NC groups were defined primarily using a composite measure of memory performance (the decline in Z mem for the Converters (C pre versus C post ) is shown Fig. 1a) . In addition, Plasma phospholipids identify antecedent memory impairment in older adults composite measures of other cognitive abilities ( Supplementary  Fig. 2 ) and measures of memory complaints and functional capacities were compiled (Supplementary Tables 2 and 3) . The discovery and validation groups did not differ on clinical measures (F(4,170) = 1.376, P = 0.244) or on any composite z-score (F(5,169) = 2.118, P = 0.066), demonstrating the general equivalence of the participants used for the discovery and validation phases of the biomarker analysis.
We examined 124 plasma samples from the 106 discovery-phase participants for untargeted metabolomic analysis (Online Methods). Metabolomic and lipidomic profiling yielded 2,700 positive-mode features and 1,900 negative-mode features. Metabolites defining the participant groups were selected using the least absolute shrinkage and selection operator (LASSO) penalty 8, 9 . The LASSO analysis revealed features that assisted in unambiguous class separation between the two nonimpaired groups, the Converter pre group and the NC subjects who do not phenoconvert ( Table 1) . This untargeted analysis revealed considerably lower phosphatidylinositol in the Converter pre group and higher glycoursodeoxycholic acid in the aMCI/AD group compared to the NC group. These metabolites were unambiguously identified using tandem mass spectrometry (Supplementary Fig. 3 ).
The untargeted LASSO analysis revealed amino acids and phospholipids to be potent discriminators of the NC and aMCI/AD groups. Thus, we performed stable isotope dilution-multiple reaction monitoring (MRM) mass spectrometry (SID-MRM-MS) to unambiguously identify and quantify lipids, amino acids and biogenic amines; this would discriminate our groups with emphasis on differences that might predict phenoconversion from NC to aMCI/AD. This targeted analysis revealed significantly lower plasma levels of serotonin, phenylalanine, proline, lysine, phosphatidylcholine (PC), taurine and acylcarnitine (AC) in Converter pre participants who later phenoconverted to aMCI/AD ( Table 2) .
A notable finding of this targeted metabolomic and lipidomic analysis was the identification of a set of ten metabolites, comprising PCs, (PC diacyl (aa) C36:6, PC aa C38:0, PC aa C38:6, PC aa C40:1, PC aa Table 3 ).
The performance of the Converter group (C pre , Converters at baseline) after phenoconversion (C post ) is plotted for direct comparison. The plot shows Z mem , as described in Supplementary Table 3 The P values for analytes between groups were P ≤ 0.05. The two metabolites with P values <0.005 are indicated with an asterisk. Each Kruskal-Wallis test was followed by Mann-Whitney U-tests for post hoc pairwise comparisons (NC versus C pre and NC versus aMCI/AD). Significance was adjusted for multiple comparisons using Bonferroni's method (P < 0.025). npg C40:2, PC aa C40:6, PC acyl-alkyl (ae) C40:6), lysophophatidylcholine (lysoPC a C18:2), and acylcarnitines (ACs) (Propionyl AC (C3) and C16:1-OH) that were depleted in the plasma of the Converter pre participants but not in that of the NC group (Fig. 1b) . These metabolites remained depleted after phenoconversion to aMCI/AD (Converters post ) and were similar to the levels in the aMCI/AD group. We then performed targeted quantitative metabolomic and lipidomic analyses using plasma from a separate group of 40 participants as an independent blinded cross-validation, as one sample from the aMCI/AD group was not available for lipidomic analysis. The validation samples were obtained from those clinically defined NC, Converter pre , aMCI/AD subjects. The samples were processed and analyzed using the same SID-MRM-MS technique as in the discovery phase. The targeted quantitative analysis of the validation set revealed similar levels for the ten-metabolite panel ( Supplementary  Fig. 4 ) as were observed in the discovery samples (Fig. 1b) .
We used the metabolomic data from the untargeted LASSO analysis to build separate linear classifier models that would distinguish the aMCI/AD and Converter pre groups from the NC group. We used receiver operating characteristic (ROC) analysis to assess the performance of the classifier models for group classification. For the Converter pre and NC group classification, the initial LASSO-identified metabolites yielded a robust area under the curve (AUC) of 0.96 (Fig. 2a) and a more modest AUC of 0.83 for aMCI/AD and NC group classification. A separate classifier model using the discovered ten-metabolite panel from the targeted metabolomic analysis classified Converter pre and NC participants with an AUC of 0.96 (Fig. 2b) and an AUC of 0.827 for the aMCI/AD versus NC classification. To validate our biomarker-based group classification, we applied the same simple logistic classifier model developed for the discovery samples to the independent validation samples. The model classified Converter pre and NC participants with an AUC of 0.92 (Fig. 2c) and an AUC of 0.77 for the aMCI/AD versus NC groups. This model yielded a sensitivity of 90% and specificity of 90%, for classifying the Converter pre and NC groups in the validation phase (Fig. 2c) .
We then considered the effects of apolipoprotein E (APOE) genotype on our classification of the Converter pre and NC groups. APOE is involved in lipid metabolism, with the ε4 allele known to be a risk factor for AD. The proportion of ε4 allele carriers was similar in the aMCI/AD (19/69 = 27.5%), NC (17/73 = 23%) and Converter (5/28 = 17%) groups (χ 2 = 0.19, P = 0.68, not significant). We repeated the classification analyses using the ten-metabolite model with APO ε4 allele as a covariate. The effect of the ε4 allele was not significant (P = 0.817), and classification accuracy for Converter pre and NC groups changed minimally from an AUC 0.96 to 0.968 (P = 0.992, not significant). Furthermore, a classifier model using only APOE ε4 produced an AUC of 0.54 for classifying the Converter pre and NC groups, implying virtually random classification. These findings indicate that the presumed pathophysiology reflected by the ten-metabolite biomarker panel is orthogonal to APOE-mediated effects.
Here we present the discovery and validation of plasma metabolite changes that distinguish cognitively normal participants who will progress to have either aMCI or AD within 2-3 years from those destined to remain cognitively normal in the near future. The defined ten-metabolite profile features PCs and ACs, phospholipids that have essential structural and functional roles in the integrity and functionality of cell membranes 10, 11 . Deficits of the plasmalemma in AD have been described previously 12 . Studies have shown decreased plasma PC levels 13 and lysoPC/PC ratios 14 and increased cerebrospinal fluid (CSF) PC metabolites in patients with AD 15 , as well as decreased phosphatidylinositol in the hippocampus 16 and other heteromodal cortical regions 17 . Furthermore, amyloid-β may directly disrupt bilayer integrity by interacting with phospholipids 18 . ACs are known to have a major role in central carbon and lipid metabolism occurring within the mitochondria 11 . They have also been associated with regulation, production and maintenance of neurons through enhancement of nerve growth factor production 11 , which is a known potent survival and trophic factor for brain cholinergic neurons, particularly those consistently affected by AD within the basal forebrain [19] [20] [21] . Decreasing plasma AC levels in the Converter pre participants in our study may indirectly signal an impending dementia cascade that features loss of these cholinergic neuronal populations. We posit that this ten-phospholipid biomarker panel, consisting of PC and AC species, reveals the breakdown of neural cell membranes in those individuals destined to phenoconvert from cognitive intactness to Simple logistic models using only the metabolites identified in each phase of the lipidomics analysis were developed and applied to determine the success of the models for classifying the C pre and NC groups. The red line in each plot represents the AUC obtained from the discovery-phase LASSO analysis (a), the targeted analysis of the ten metabolites in the discovery phase (b) and the application of the ten-metabolite panel developed from the targeted discovery phase in the independent validation phase (c). The ROC plots represent sensitivity (i.e., true positive rate) versus 1 -specificity (i.e., false positive rate).
npg aMCI or AD and may mark the transition between preclinical states where synaptic dysfunction and early neurodegeneration give rise to subtle cognitive changes 2 . Most approaches to fluid-based biomarker discovery have focused on amyloid-β 1-42 (Aβ42), total tau and phosphorylated tau-181 obtained from CSF. Classification of symptomatic patients versus normal controls or other dementias or conversion from MCI to AD is high 22 , but the predictive value of these CSF biomarkers in preclinical patients is not as strong, suggesting that these markers may be useful only for confirmation of clinical diagnosis 23 . Blood-based biomarkers are not routinely used in clinical practice but may be more useful because they are easily obtained with less risk of complication in older adults. Studies focusing on Aβ42 or Aβ42/tau ratios derived from blood have been disappointing 24 , but recent studies suggest that assessment of the proteome and metabolome in blood may have more promise. One recent study using plasma identified 18 proteins that discriminated subjects with symptomatic AD from normal control subjects with nearly 90% accuracy and predicted conversion from symptomatic MCI to AD with 91% accuracy 25 . Another crosssectional study reported 18 plasma biomarkers, many related to inflammation, that correctly classified subjects with symptomatic AD and normal control subjects with a sensitivity and specificity of 85% and an AUC of 93% (ref. 26 ). The biomarker panel was externally validated in a cohort of normal control subjects and subjects with symptomatic AD with sensitivity and specificity of 80% and an AUC of 85%.
To our knowledge, this is the first published report of a blood-based biomarker panel with very high accuracy for detecting preclinical AD. This metabolic panel robustly identifies (with accuracy above 90%) cognitively normal individuals who, on average, will phenoconvert to aMCI or AD within 2-3 years. The accuracy for detection is equal to or greater than that obtained from most published CSF studies 27, 28 , and blood is easier to obtain and costs less to acquire, making it more useful for screening in large-scale clinical trials and for future clinical use. This biomarker panel requires external validation using similar rigorous clinical classification before further development for clinical use. Such additional validation should be considered in a more diverse demographic group than our initial cohort. We consider our results a major step toward the NIA-AA (National Institute on Aging and Alzheimer's Association) consensus statement mandate for biomarkers of preclinical AD 2 .
MeTHoDS
Methods and any associated references are available in the online version of the paper.
Accession codes. Lipodomics data were deposited in the European
Bioinformatics Institute MetaboLights database with accession code MTBLS72.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
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We thank E. Johnson and D. Greenia for study coordination; P. Bailie, M. Patel and A. Balasubramanian for assistance with data collection; and A. Almudevar for statistical support. We also thank R. Padilla and I. Conteh for processing the blood samples and R. Singh and P. Kaur for technical assistance in developing the lipidomics data. This work was funded by US National Institutes of Health grants R01AG030753 and DOD W81XWH-09-1-0107 to H.J.F. The UPLC gradient consisted of 98% A and 2% B for 0.5 min and then a ramp of curve 6 to 60% B and 40% A from 0.5 min to 4.0 min, followed by a ramp of curve 6 to 98% B and 2% A from 4.0 to 8.0 min, a ramp to 5% B and 95% C from 9.0 min to 10.0 min at a flow rate of 0.4 mL/min and finally a ramp to 98% A and 2% B from 11.0 min to 13 min. The column eluent was introduced directly into the mass spectrometer by electrospray ionization. Mass spectrometry was performed on a quadrupole time-of-flight (Q-TOF) instrument (Xevo G2 QTOF, Waters Corporation, USA) operating in either negative (ESI − ) or positive (ESI + ) electrospray ionization mode with a capillary voltage of 3,200 V in positive mode and 2,800 V in negative mode and a sampling cone voltage of 30 V in both modes. The desolvation gas flow was set to 750 l h −1 , and the temperature was set to 350 °C. The source temperature was set at 120 °C. Accurate mass was maintained by introduction of a lock-spray interface of leucine-enkephalin (556.2771 [M+H] + or 554.2615 [M-H] − ) at a concentration of 2 pg/µL in 50% aqueous acetonitrile and a rate of 2 µL/min. Data were acquired in centroid MS mode from 50 to 1,200 m/z mass range for TOF-MS scanning as single injection per sample, and the batch acquisition was repeated to check experimental reproducibility. For the metabolomics profiling experiments, pooled quality control (QC) samples (generated by taking an equal aliquot of all the samples included in the experiment) were run at the beginning of the sample queue for column conditioning and every ten injections thereafter to assess inconsistencies that are particularly evident in large batch acquisitions in terms of retention time drifts and variation in ion intensity over time. This approach has been recommended and used as a standard practice by leading metabolomics researchers 33 . A test mix of standard metabolites was run at the beginning and at the end of the run to evaluate instrument performance with respect to sensitivity and mass accuracy. The overlay of the total ion chromatograms of the quality control samples depicted excellent retention time reproducibility. The sample queue was randomized to remove bias.
AUTHoR CoNTRIBUTIoNS
Stable isotope dilution-multiple reaction monitoring mass spectrometry. LC-MSmass spectrometry (LC-MS/MS) is increasingly used in clinical settings
for quantitative assay of small molecules and peptides such as vitamin D, serum bile acid and parathyroid hormone under Clinical Laboratory Improvement Amendments environments with high sensitivities and specificities 34 . In this study, targeted metabolomic analysis of plasma samples was performed using the Biocrates Absolute-IDQ P180 (BIOCRATES, Life Science AG, Innsbruck, Austria). This validated targeted assay allows for simultaneous detection and quantification of metabolites in plasma samples (10 µL) in a high-throughput manner. The methods have been described in detail 35, 36 . The plasma samples were processed as per the instructions by the manufacturer and analyzed on a triple-quadrupole mass spectrometer (Xevo TQ-S, Waters Corporation, USA) operating in the MRM mode. The measurements were made in a 96-well format for a total of 148 samples, and seven calibration standards and three quality control samples were integrated in the kit. Briefly, the flow injection analysis tandem mass spectrometry (MS/MS) method was used to quantify a panel of 144 lipids simultaneously by multiple reaction monitoring. The other metabolites are resolved on the UPLC and quantified using scheduled MRMs. The kit facilitates absolute quantitation of 21 amino acids, hexose, carnitine, 39 acylcarnitines, 15 sphingomyelins, 90 phosphatidylcholines and 19 biogenic amines. Data analysis was performed using the MetIQ software (Biocrates), and the statistical analyses included the nonparametric Kruskal-Wallis test with follow-up Mann-Whitney U-tests for pairwise comparisons using the STAT pack module v3 (Biocrates). Significance was adjusted for multiple comparisons using Bonferroni's method (P < 0.025). The abundance is calculated from area under the curve by normalizing to the respective isotope labeled internal standard. The concentration is expressed as nmol/L. Human EDTA plasma samples spiked with standard metabolites were used as quality control samples to assess reproducibility of the assay. The mean of the coefficient of variation (CV) for the 180 metabolites was 0.08, and 95% of the metabolites had a CV of <0.15.
Sample size considerations. The signal intensity of the metabolites within similar groups was normally distributed with a standard deviation of 1.5. If the true difference in the Converterpre and NC groups' mean is twofold, we will have over 90% power to detect differential metabolites at an overall significance level of 5% with Bonferroni's adjustment using 30 subjects per group.
Lipidomics statistical analyses.
The m/z features of metabolites were normalized with log transformation that stabilized the variance, followed by a quantile normalization to make the empirical distribution of intensities the same across samples 37 . The metabolites were selected among all those known to be identifiable using a ROC regularized learning technique 38, 39 based on the LASSO penalty 8, 9 as implemented with the R package 'glmnet' 40 , which uses cyclical coordinate descent in a path-wise fashion. We first obtained the regularization path over a grid of values for the tuning parameter λ through tenfold cross-validation. The optimal value of the tuning parameter lambda, which was obtained by the cross-validation procedure, was then used to fit the model. All the features with nonzero coefficients were retained for subsequent analysis. This technique is known to reduce overfitting and achieve similar prediction accuracy as the sparse supporting vector machine. The classification performance of the selected metabolites was assessed using area under the ROC curve (AUC). The ROC can be understood as a plot of the probability of classifying correctly the positive samples against the rate of incorrectly classifying true negative samples. So the AUC measure of an ROC plot is a measure of predictive accuracy. To maintain rigor of independent validation, the simple logistic model with the ten-metabolite panel was used, although a more refined model can yield greater AUC. The validation phase was performed in a blinded fashion such that the sample group was not known by the statistical team.
